Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narsoplimab - Omeros Corporation

Drug Profile

Narsoplimab - Omeros Corporation

Alternative Names: anti-MASP-2 monoclonal antibody; MASP-2 antibody - Omeros Corporation; MASP-2 therapeutic; OMS 00620646; OMS 620646; OMS 721

Latest Information Update: 13 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Omeros Corporation
  • Developer Omeros Corporation; Quantum Leap Healthcare Collaborative
  • Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics; Vascular disorder therapies
  • Mechanism of Action Immunomodulators; MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic microangiopathies; IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Thrombotic microangiopathies
  • Phase III Haemolytic uraemic syndrome; IgA nephropathy; Immediate hypersensitivity
  • Phase II Glomerulonephritis; Lupus nephritis; Membranous glomerulonephritis; SARS-CoV-2 acute respiratory disease
  • No development reported Stroke; Wet age-related macular degeneration

Most Recent Events

  • 09 Nov 2023 Omeros Corporation expects a decision from the US FDA regarding the approval of narsoplimab for Thrombotic microangiopathies, in mid 2024
  • 16 Oct 2023 Omeros Corporation discontinues a phase III ARTEMIS-IGAN trial in IgA nephropathy in Sweden, Czech Republic, Spain, Slovakia, Poland, Lithuania, Hungary, Bulgaria, Belgium, Austria and Australia (IV), due to absence of statistical significance (NCT03608033)
  • 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in SARS-COV-2 acute respiratory disease in Italy (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top